Package Leaflet: Information for the Patient
Kaftrio 37.5mg/25mg/50mg film-coated tablets
Kaftrio75mg/50mg/100mg film-coated tablets
ivacaftor/tezacaftor/elexacaftor
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Kaftrio contains three active substances:ivacaftor, tezacaftor and elexacaftor. This medicine helps the lung cells to work better in some patients with cystic fibrosis (CF). CF is an inherited condition where the lungs and digestive system can become clogged with thick, sticky mucus.
Kaftrio taken with ivacaftor is for patientsfrom6years of age who have CF withat least one mutationin the CFTR(cystic fibrosis transmembrane conductance regulator) gene that responds to Kaftrio. The medicine is intended as a long-term treatment.
Kaftrio works on a protein called CFTR. The protein is damaged in some people with CF if they have a mutation in the CFTRgene.
Kaftrio is usually taken with another medicine,ivacaftor. Ivacaftor makes the protein work better while tezacaftor and elexacaftor increase the amount of protein on the cell surface.
Kaftrio (taken together with ivacaftor) helps you breathe better by improving your lung function. You may also notice that you do not get ill as often or that it is easier to gain weight.
Do not takeKaftrio
Consult your doctorand do not take the tablets if this applies to you.
Warnings and precautions
Tell your doctor immediatelyif you have any symptoms that may indicate liver problems. These are listed in section 4.
Consult your doctor if you notice changes in your child's behaviourin the first 2 months of treatment.
Childrenunder 6years
Do not give this medicine to children under 6 years as it is not known if Kaftrio tablets are safe and effective in this age group.
Other medicines andKaftrio
Tell your doctor or pharmacistif you are taking, have recently taken or might take any other medicines. Some medicines may affect how Kaftrio works or may increase the chance of side effects. In particular, tell your doctor if you are taking any of the medicines listed below. Your doctor may need to change the dose of one of your medicines if you are taking some of these.
Taking Kaftrio withfood and drink
Avoid foods or drinks that contain grapefruit during treatment as they may increase the side effects of Kaftrio by increasing the amount of Kaftrio in the body.
Pregnancy and breast-feeding
Driving and using machines
Kaftrio may cause dizziness. If you feel dizzy, do not drive, ride a bicycle or use machines unless you are sure that you are not affected.
Kaftrio contains sodium
This medicinecontainsless than 23 mg of sodium (1 mmol) per dose; this is, essentially “sodium-free”.
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, check with your doctor or pharmacist.
Your doctor will decide the correct dose for you.
Kaftrio is usually taken with ivacaftor.
Recommended dose for patients 6years of age and older
Age | Weight | Morning dose | Evening dose |
6 years to <12 years | <30 kg | Two 37.5 mg ivacaftor/25 mg tezacaftor/50 mg elexacaftor tablets | One 75 mg ivacaftor tablet |
6 years to <12 years | ≥30 kg | Two 75 mg ivacaftor/50 mg tezacaftor/100 mg elexacaftor tablets | One 150 mg ivacaftor tablet |
12 years or older | - | Two 75 mg ivacaftor/50 mg tezacaftor/100 mg elexacaftor tablets | One 150 mg ivacaftor tablet |
Take the morning and evening tablets with an interval of about 12 hours.
The tablets are taken by mouth.
Take the Kaftrio and ivacaftor tablets withfat-containing foods. Fat-containing meals or snacks are those prepared with butter or oils or those that contain eggs. Examples of other fat-containing foods are:
Avoid foods and drinks that contain grapefruit while taking Kaftrio. See Taking Kaftrio with food and drinkin section 2 for more information.
Swallow the tablets whole.Do not chew, crush or break the tablets before swallowing.
You should continue to take all your other medicines as well unless your doctor tells you to stop.
If you have liver problems,your doctor may reduce your dose of Kaftrio tablets or decide to stop your treatment with Kaftrio. See Warnings and precautionsin section 2.
If you take moreKaftriothan you should
Consult your doctor or pharmacist.If possible, take the medicine and this leaflet with you. You may experience side effects, including those mentioned in section 4 below.
If you forget to takeKaftrio
If you miss a dose, calculate how much time has passed since the time you should have taken the dose.
Do nottake a double dose to make up for a forgotten dose.
If you stop takingKaftrio
Your doctor will tell you how long you need to take Kaftrio. It is important that you take this medicine regularly. Do not make any changes unless your doctor tells you to.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects
Signs of liver problems
Liver damage and worsening of liver functionin people with or without liver disease. Worsening of liver function may be severe and may require a transplant (see section 2).
Increased liver enzymes in the blood are common in patients with Kaftrio. The following may be signs of liver problems:
Depression.Signs include feeling sad or having mood changes, anxiety, feeling emotionally upset.
Tell your doctor immediatelyif you get any of these symptoms.
Very common side effects(may affect more than 1 in 10 people)
Tell your doctor immediatelyif you get a rash.
Other side effects:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Frequency not known(cannot be estimated from the available data)
Additional side effects in adolescents
Side effects seen in adolescents are similar to those seen in adults.
Additional side effects in children
Most cases of changes in behaviour have been reported in young children aged 2 to 5 years.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP. The expiry date is the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
Composition ofKaftrio
Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets
Each film-coated tablet contains 37.5 mg of ivacaftor, 25 mg of tezacaftor, and 50 mg of elexacaftor.
Kaftrio 75 mg/50 mg/100 mg film-coated tablets
Each film-coated tablet contains 75 mg of ivacaftor, 50 mg of tezacaftor, and 100 mg of elexacaftor.
See the end of section 2 for important information about the contents of Kaftrio.
Appearance and Package Contents
Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets are capsule-shaped, light orange tablets with the imprint “T50” on one side and smooth on the other.
Kaftrio 75 mg/50 mg/100 mg film-coated tablets are capsule-shaped, orange tablets with the imprint “T100” on one side and smooth on the other.
Kaftrio is available in pack sizes of 56 tablets (4 blister packs of 14 tablets each).
Marketing Authorization Holder
Vertex Pharmaceuticals (Ireland) Limited
Unit 49, Block 5, Northwood Court, Northwood Crescent,
Dublin 9, D09 T665,
Ireland
Tel.: +353 (0)1 761 7299
Manufacturer
Almac Pharma Services (Ireland) Limited
Finnabair Industrial Estate
Dundalk
Co. Louth
A91 P9KD
Ireland
Almac Pharma Services Limited
Seagoe Industrial Estate
Craigavon
Northern Ireland
BT63 5UA
United Kingdom
You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder:
Spain Vertex Pharmaceuticals Spain, S.L. Tel: + 34 91 7892800 | |
Greece Vertex Φαρμακευτικ? Μονοπρ?σωπη Αν?νυμη Εταιρ?α Tel: +30 (211) 2120535 | Italy Vertex Pharmaceuticals (Italy) S.r.l. Tel: +39 0697794000 |
Date of the last revision of this leaflet:
Other Sources of Information
Detailed information on this medicinal product is available on the European Medicines Agency website: https://www.ema.europa.eu. There are also links to other websites on rare diseases and orphan medicines.